Phibro Long Term Investments vs Capital Surpluse Analysis
PAHC Stock | USD 23.59 0.02 0.08% |
Phibro Animal financial indicator trend analysis is much more than just breaking down Phibro Animal Health prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Phibro Animal Health is a good investment. Please check the relationship between Phibro Animal Long Term Investments and its Capital Surpluse accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Phibro Animal Health. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
Long Term Investments vs Capital Surpluse
Long Term Investments vs Capital Surpluse Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Phibro Animal Health Long Term Investments account and Capital Surpluse. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Phibro Animal's Long Term Investments and Capital Surpluse is 0.82. Overlapping area represents the amount of variation of Long Term Investments that can explain the historical movement of Capital Surpluse in the same time period over historical financial statements of Phibro Animal Health, assuming nothing else is changed. The correlation between historical values of Phibro Animal's Long Term Investments and Capital Surpluse is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Long Term Investments of Phibro Animal Health are associated (or correlated) with its Capital Surpluse. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Surpluse has no effect on the direction of Long Term Investments i.e., Phibro Animal's Long Term Investments and Capital Surpluse go up and down completely randomly.
Correlation Coefficient | 0.82 |
Relationship Direction | Positive |
Relationship Strength | Strong |
Long Term Investments
Long Term Investments is an item on the asset side of Phibro Animal balance sheet that represents investments Phibro Animal Health intends to hold for over a year. Phibro Animal Health long term investments may include different instruments such as stocks, bonds, real estate and cash.Capital Surpluse
Most indicators from Phibro Animal's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Phibro Animal Health current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Phibro Animal Health. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. At present, Phibro Animal's Enterprise Value Over EBITDA is projected to decrease significantly based on the last few years of reporting. The current year's Enterprise Value Multiple is expected to grow to 17.41, whereas Selling General Administrative is forecasted to decline to about 139.2 M.
2022 | 2023 | 2024 (projected) | Interest Expense | 17.9M | 22.0M | 18.1M | Depreciation And Amortization | 34.0M | 36.2M | 38.0M |
Phibro Animal fundamental ratios Correlations
Click cells to compare fundamentals
Phibro Animal Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Phibro Animal fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 784.1M | 841.3M | 931.7M | 971.4M | 982.2M | 568.4M | |
Short Long Term Debt Total | 410.7M | 426.7M | 470.5M | 510.0M | 525.5M | 335.6M | |
Other Current Liab | 21.2M | 70.3M | 67.0M | 60.4M | 78.4M | 50.1M | |
Total Current Liabilities | 157.2M | 164.1M | 190.8M | 176M | 204.1M | 141.8M | |
Total Stockholder Equity | 188.2M | 238.5M | 262.4M | 282.5M | 256.6M | 269.5M | |
Other Liab | 46.7M | 28.0M | 29.0M | 31.3M | 36.0M | 39.1M | |
Property Plant And Equipment Net | 171.0M | 187.7M | 203.2M | 231.3M | 240.9M | 130.8M | |
Net Debt | 374.4M | 376.5M | 396.2M | 468.7M | 454.8M | 301.8M | |
Retained Earnings | 183.1M | 218.0M | 247.7M | 260.9M | 243.9M | 256.1M | |
Accounts Payable | 66.1M | 68.4M | 95.6M | 73.9M | 85.6M | 64.0M | |
Cash | 36.3M | 50.2M | 74.2M | 41.3M | 70.6M | 74.1M | |
Non Current Assets Total | 332.3M | 342.4M | 365.5M | 385.7M | 381.2M | 224.4M | |
Non Currrent Assets Other | 16.2M | 19.8M | 29.0M | 26.3M | 9.8M | 15.2M | |
Other Assets | 33.4M | 35.6M | 28.0M | 30.8M | 35.5M | 27.9M | |
Long Term Debt | 368.3M | 382.7M | 417.9M | 452.5M | 458.3M | 250.9M | |
Cash And Short Term Investments | 91.3M | 93.2M | 91.2M | 81.3M | 114.6M | 120.3M | |
Net Receivables | 126.5M | 146.9M | 166.5M | 163.5M | 169.5M | 119.4M | |
Liabilities And Stockholders Equity | 784.1M | 841.3M | 931.7M | 971.4M | 982.2M | 586.5M | |
Non Current Liabilities Total | 438.7M | 438.7M | 478.4M | 512.9M | 521.4M | 369.7M | |
Inventory | 196.7M | 216.3M | 259.2M | 277.6M | 265.9M | 160.7M | |
Other Current Assets | 37.3M | 42.5M | 49.3M | 63.4M | 51.0M | 29.0M | |
Other Stockholder Equity | 129.9M | 133.3M | 135.5M | 135.8M | 136.3M | 143.1M | |
Total Liab | 595.9M | 602.8M | 669.3M | 688.9M | 725.5M | 507.4M | |
Property Plant And Equipment Gross | 171.0M | 187.7M | 444.1M | 495.0M | 486.3M | 510.6M | |
Total Current Assets | 451.8M | 498.9M | 566.2M | 585.7M | 601.0M | 362.1M | |
Accumulated Other Comprehensive Income | (130.4M) | (115.3M) | (121.1M) | (114.2M) | (123.5M) | (117.4M) | |
Short Term Debt | 25.2M | 19.3M | 21.1M | 33.1M | 37.3M | 18.8M | |
Intangible Assets | 71.0M | 62.3M | 63.9M | 55.0M | 45.0M | 34.7M | |
Property Plant Equipment | 171.0M | 187.7M | 165.5M | 195.6M | 224.9M | 121.5M | |
Net Tangible Assets | 64.5M | 123.6M | 145.4M | 174.2M | 200.4M | 210.4M | |
Current Deferred Revenue | 44.8M | 58.9M | 822K | 54.9M | 2.9M | 2.8M | |
Retained Earnings Total Equity | 183.1M | 218.0M | 247.7M | 260.9M | 300.0M | 315.1M | |
Short Term Investments | 55M | 43M | 17M | 40M | 44M | 27.9M | |
Deferred Long Term Liab | 1.0M | 1.8M | 1.4M | 1.4M | 1.3M | 1.4M | |
Short Long Term Debt | 18.8M | 9.4M | 15M | 22.3M | 29.8M | 30.7M | |
Long Term Debt Total | 229.8M | 217.6M | 417.9M | 452.5M | 520.4M | 333.8M | |
Capital Surpluse | 129.9M | 133.3M | 135.5M | 135.8M | 156.2M | 142.6M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Phibro Animal Health offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Phibro Animal's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Phibro Animal Health Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Phibro Animal Health Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Phibro Animal Health. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Phibro Animal. If investors know Phibro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Phibro Animal listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.94) | Dividend Share 0.48 | Earnings Share 0.43 | Revenue Per Share 25.843 | Quarterly Revenue Growth 0.126 |
The market value of Phibro Animal Health is measured differently than its book value, which is the value of Phibro that is recorded on the company's balance sheet. Investors also form their own opinion of Phibro Animal's value that differs from its market value or its book value, called intrinsic value, which is Phibro Animal's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Phibro Animal's market value can be influenced by many factors that don't directly affect Phibro Animal's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Phibro Animal's value and its price as these two are different measures arrived at by different means. Investors typically determine if Phibro Animal is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Phibro Animal's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.